400-920-2911 sales@csnpharm.cn
CAS No.: 187389-52-2
Synonyms: Z-Val-Ala-Asp(OMe)-FMK;Z-VAD-FMK;Z-Val-Ala-Asp-(OMe)-Fluoromethyl Ketone
Z-VAD(OMe)-FMK is a cell-permeable, irreversible broad-spectrum caspase inhibitor, blocks all features of apoptosis.
生物活性
实验方案
技术信息
CAS号 | 187389-52-2 | 储存条件 |
|
|||||||||||||
分子式 | C22H30FN3O7 | 运输 | 蓝冰 | |||||||||||||
分子量 | 467.49 | 别名 | Z-Val-Ala-Asp(OMe)-FMK;Z-VAD-FMK;Z-Val-Ala-Asp-(OMe)-Fluoromethyl Ketone | |||||||||||||
溶解度 |
|
动物实验配方 |
|
Cell Lines | Concentration | Assay Type | Time | Activity Description | Data Sources |
---|
3T9 MEFs | - | Function Assay | 16h | increases cytochrome c release after etoposide-treatment | 22613767 |
3T9 MEFs | - | Function Assay | 18h | upregulates initiator caspase-9 but downregulates effector caspases after etoposide treatment | 22613767 |
4T1 | 2.5-10μM | Cell Viability Assay | 4h | rescues the cytotoxicity of 4T1 cells induced by SPDT in a concentration dependent manner | 24206161 |
5637 | 20μM | Apoptosis Assay | 1h | reverses CM-induced cell death | 24282433 |
769-P | 40μM | Apoptosis Assay | 48h | reduces the number of Annexin V-positive cells | 25279191 |
A2750 | 20μM | Apoptosis Assay | 2h | blocks caspase cleavage during helenalin treatment and reduces autophagic cell death | 22784363 |
A375 | 30μM | Apoptosis Assay | 2h | prevents the drug-induced PARP cleavage | 25376115 |
A375 | 20μM | Apoptosis Assay | 24h | reverses dicitrinone B-induced apoptosis | 24699111 |
A431 | 40μM | Kinase Assay | 2h | blocks fisetin-induced cleavage of caspases and PARP | 23800058 |
A549 | 20 μM | Apoptosis Assay | 24h | reduces cell death caused by HFCP treatment | 25794149 |
A549 | 10 μM | Apoptosis Assay | 24h | promotes HBC-treated A549 cell survival & attenuates the cleaved PARP expression | 25683568 |
A549 | 10μM | Apoptosis Assay | 24h | blocks DMAS-induced cleavage of caspase-3 and PARP and apoptotic cell death | 25434989 |
A549 | 50μM | Apoptosis Assay | 24h | reverses ribosome biogenesis and apoptosis caused by Chijongdan | 25349781 |
A549 | 2.5-25μM | Apoptosis Assay | 1h | decreases the population of apoptotic cells depend on concentrations | 25342427 |
A549 | 10μM | Apoptosis Assay | 3h | reduces cell apoptosis caused by PQQ | 25161699 |
A549 | 50µM | Apoptosis Assay | 2h | prevents the hypodiploid DNA content phase induced by cephalochromin | 24588135 |
A549 | 5μM | Apoptosis Assay | 24h | suppresses 6e (BK10040)-induced apoptosis | 24529871 |
A549 | 100μM | Apoptosis Assay | 48h | suppresses the apoptosis caused by piperine | 24272201 |
A549 | 2.5μM | Apoptosis Assay | 24h | decreases oridonin-induced autophagy as well and Loss of Δψm also occurred during autophagic process | 24102522 |
A549 | 50μM | Apoptosis Assay | 1h | blocks the BAI-induced apoptosis | 22887215 |
A549 | 50μM | Apoptosis Assay | 2h | partially decreases sodium selenite-induced apoptosis | 22721804 |
A549 | 50μM | Apoptosis Assay | 1h | prevents apoptosis induced by Baohuoside I | 22687635 |
A549/V16 | 50μM | Apoptosis Assay | 1h | represses TG/TM-induced apoptosis | 25946033 |
ACH-2 | 0-200μM | Apoptosis Assay | 2h | reduces drug-induced apoptosis and subsequent HIV-1 replication in a dose-dependent manner | 25980942 |
ADF | 40μM | Apoptosis Assay | 6h | inhibits apoptosis induced by chemotherapy plus ZnCl2 | 24228232 |
AGS | 10μM | Apoptosis Assay | 1h | prevents curcumin-induced cleavage of caspase-3, -8, and -9 proteins | 25492214 |
AGS | 50μM | Apoptosis Assay | 24h | abolishs β-lapachone-induced cell death and inhibited growth | 25009698 |
AGS | 20μM | Apoptosis Assay | 12h | reduces the induction of apoptosis in response to the EtOAc fraction in a dose-dependent manner | 24789703 |
AGS | 20μM | Apoptosis Assay | 12h | inhibits the activation of pro-caspase-3 in response to the EtOAc fraction | 22687398 |
astrocytes cell | 40μM | Apoptosis Assay | 6h | reduces early apoptosis induced by staurosporine | 23411778 |
BCC | 50μM | Apoptosis Assay | 1h | inhibits DATS-mediated growth inhibition | 22519436 |
BEL-7402 | 20μM | Apoptosis Assay | 1h | attenuated the apoptotic induction of III-10 | 26164795 |
Bel-7402 | 50μM | Caspase Activation Assay | 2h | inhibits PCE-induced anoikis | 23008742 |
Bel-7402 | 50μM | Apoptosis Assay | 2h | inhibits PCE-induced anoikis | 23008742 |
BGC-823 | 10 μM | Apoptosis Assay | 24h | reduces tetrandrine-induced apoptosis | 24098511 |
BGC-823 | 100μM | Apoptosis Assay | 1h | partially rescues cells against damage of daidzein | 22926545 |
BV-2 | 20μM | Apoptosis Assay | 2h | suppresses UV-induced chromatin extrusion and dilation of the nuclear envelope | 24558118 |
C6 | 50μM | Apoptosis Assay | 48h | prevents the loss of cell viability caused by pregnenolone | 25013479 |
C6 | 10μM | Apoptosis Assay | 24h | blocks the suppressive effect of the peptide on viability | 22588980 |
C666-1 | 50μM | Apoptosis Assay | 24h | suppresses the cleavage of PARP and caspase-3, -7, and -9 induced by bortezomib/SAHA | 23475956 |
Caco-2 | 40 μM | Apoptosis Assay | 4h | prevents ST-7-induced ZO-1 changes and TER drop | 24822183 |
Caki-1 | 40μM | Apoptosis Assay | 48h | reduces the number of Annexin V-positive cells | 25279191 |
Caki-1 | 20μM | Apoptosis Assay | 1h | inhibits SCP-induced apoptosis | 24504681 |
CAL27 | 10 μM | Apoptosis Assay | 2h | suppresses Cur-NPs-reduced viability by up to 90% | 23917396 |
CEF | 0,33,67,100μM | Kinase Assay | 15min | down-regulates PR enzyme activity to 40% at 100μM | 26102339 |
CL-1 | 20μM | Apoptosis Assay | 1h | blocks OP449 induced cell death | 23131782 |
CLL | 25μM | Apoptosis Assay | 1h | partially blocks MLN2238-induced cell apoptosis | 24467634 |
CNE1 | 20μM | Apoptosis Assay | 48h | blocks LK-A-induced apoptosis | 23985029 |
CNE-1 | 20μM | Apoptosis Assay | 24h | inhibits RAD001-induced cell death | 23426850 |
CNE2 | 20μM | Apoptosis Assay | 48h | blocks LK-A-induced apoptosis | 23985029 |
COS7 | 10μM | Kinase Assay | 24h | increases caspase 3/7 activities | 25384025 |
COS7 | 10μM | Apoptosis Assay | 48h | partially prevented FC101-induced cell death | 25384025 |
COS-7 | 50µM | Function Assay | 24h | affects the processing of ATN1s with polyQ tracts | 23933208 |
Cytotoxicity Assay | 20μM | Cell Viability Assay | 48h | prevent MHMD-induced cell death | 25392116 |
DLD1 | 20 μM | Apoptosis Assay | 1h | partly reverses cell apoptosis caused by WSP1 | 25524246 |
DM6 | 100μM | Apoptosis Assay | 72h | blocks both E2F-1 and E2Ftr-mediated cytotoxicity | 22825328 |
DTK-SME | 50μM | Apoptosis Assay | 2h | partially inhibits the apoptosis induced by bupivacaine | 25843897 |
EA.hy926 | 10μM | Apoptosis Assay | 2h | inhibits apoptosis and facilitates autophagy in DENV2-infected EA.hy926 | 25138703 |
Ebs | 10-100μM | Apoptosis Assay | 24h | MMTS generation rate decreased as the concentration of z-VAD.fmk increased | 25134817 |
EBV-transformed B cells | 20μM | Apoptosis Assay | 2h | blocks anti-CD80 and anti-CD86 antibody-induced apoptosis | 24008628 |
Ec109 | 10μM | Apoptosis Assay | 6h | blocks apoptotic combination of Tat-SmacN7 and radiation | 23338568 |
Ec-109 | 10 μM | Apoptosis Assay | 48h | represses PE-mediated Ec-109 cell apoptosis | 23782641 |
Eca-109 | 25μM | Apoptosis Assay | 30min | inhibits BJ-B11-induced cell death | 23076967 |
EMT-6 | 100μM | Cytotoxicity Assay | 1h | partially blocked cell death induced by siramesine | 22251921 |
eosinophil | 90μM | Apoptosis Assay | 24h | inhibits apoptosis induced by Fas antibody | 22079334 |
fetal rat lung fibroblasts | 80μM | Kinase Assay | 1h | inhibits Caspase-3 activity | 24314135 |
G292 | 40μM | Apoptosis Assay | 24h | blocks the increased cleavage of caspase-3 and PARP induced by BBMD3 | 24025361 |
GC1a | 50μM | Apoptosis Assay | 24h | indicates a protective effect against etoposide | 26169075 |
H460 | 10μM | Apoptosis Assay | 6h | blocks apoptotic combination of Tat-SmacN7 and radiation | 23338568 |
H929 | 100μM | Apoptosis Assay | 1h | partially blocks cell death caused by necrostatin-1 | 25037851 |
H9c2 | 50μM | Apoptosis Assay | 1h | inhibits DOX-induced caspase 3 activation but not the loss of cells | 25283819 |
HA | 50μM | Apoptosis Assay | 24h | suppresses the cleavage of PARP and caspase-3, -7, and -9 induced by bortezomib/SAHA | 23475956 |
HaCaT | 100μM | Apoptosis Assay | 1h | blunts UVB-induced apoptosis in HaCaT cells | 24356997 |
HBx | 25μM | Apoptosis Assay | 48h | reduced cell death induced by 3-MA | 22020078 |
HCC | 20 μM | Apoptosis Assay | 2h | attenuates the DHA induced activation of PARP | 22342732 |
HCC38 | 100μM | Apoptosis Assay | 1h | abrogates the induction of cell death by WEE1 inhibition, TRAIL treatment, and the combination | 22112940 |
HCEC | 50μM | Function Assay | 72h | restores of the normal HCEC phenotype | 23742011 |
hCMEC/D3 | 25μM | Apoptosis Assay | 72h | reduces LtxA induced apoptosis | 23665198 |
HCT116 | 50μM | Apoptosis Assay | 2h | inhibits the cell death induced by DDVP | 25868818 |
HCT116 | 20μM | Apoptosis Assay | 24h | abrogates of TQ-induced apoptosi | 24890449 |
HCT116 | 20μM | Apoptosis Assay | 24h | inhibits the cell apoptotic induced by YLT205 | 24713812 |
HCT116 | 100μM | Apoptosis Assay | 1.5h | inhibits Os-induced cell death | 23744353 |
HCT116 | 50 μM | Apoptosis Assay | 2h | reverses synergistic apoptosis effects of celecoxib and NPC-16 | 22159752 |
HCT116 | 50 μM | Apoptosis Assay | 24h | abrogates curcumin-induced cell death | 22101335 |
HDPC | 50µM | Apoptosis Assay | 24h | inhibits NO-induced apoptosis | 24634593 |
HEC-1B | 20μM | Apoptosis Assay | 1h | reduces TP-induced apoptosis caspase-3 and caspase-9 | 24213358 |
HeLa | 10μM | Apoptosis Assay | 48h | declines the rate of apoptosis dramatically | 25772545 |
HeLa | 40μM | Apoptosis Assay | 24h | inhibits the increased apoptosis induced by siRNF121 | 24928685 |
HeLa | 50μM | Apoptosis Assay | 72h | prevents apoptosis induced by compounds 1–5 | 24754786 |
HeLa | 100μM | Apoptosis Assay | 24h | suppresses rate of cell death induced by overexpression of G59S or G71R p150glued | 24722468 |
HeLa | 10/20μM | Apoptosis Assay | 24h | inhibits the activity of the majority of the members of the caspase-family | 24137266 |
HeLa | 20μM | Apoptosis Assay | 2h | inhibits DMMP induced apoptosis | 23863966 |
HeLa | 100μM | Apoptosis Assay | 2h | blocks JRS-15 Induces Apoptotic Cell Death | 23344045 |
HeLa | 50μM | Apoptosis Assay | 1.5h | abrogates Chlamydia-induced apoptosis | 23303804 |
HeLa | 50 μM | Apoptosis Assay | 4/8h | inhibits STS-induced late-phase apoptotic events | 22460504 |
HeLa | 50 μM | Apoptosis Assay | 1h | suppresses the FRAP-induced accumulation of annexin V positive cells | 22449440 |
HeLa | 30μM | Apoptosis Assay | 4h | increases the general cell viability 48 h after photodynamic treatment | 22394248 |
HeLa | 10μM | Apoptosis Assay | 0.5h | inhibits apoptosis induced by the combined treatment with gomisin N and TRAIL | 22179661 |
Hep-2 | 20μM | Apoptosis Assay | 24h | alleviates the decrease of cell viability induced by silibinin | 23580032 |
Hep3B | 50μM | Apoptosis Assay | 1h | blocks apoptosis induced by HEGCs | 22923154 |
Hepa1-6 | 50μM | Apoptosis Assay | 2h | inhibits curcumin and resveratrol-induced apoptosis | 23446753 |
HepG2 | 20μM | Apoptosis Assay | 1h | attenuated the apoptotic induction of III-10 | 26164795 |
HepG2 | 10μM | Apoptosis Assay | 24h | reduces vimentin cleavage caused by LPS | 24325816 |
HepG2 | 20μM | Apoptosis Assay | 30min | inhibits the enhanced cell death by combined treatment of apigenin and TRAIL | 23224239 |
HGL5 | 50μM | Apoptosis Assay | 24h | indicates a protective effect against etoposide | 26169075 |
HL60 | 40μM | Apoptosis Assay | 40min | blocks BNDC compounds induce exposure of phosphatidylserine and DNA fragmentation | 21983296 |
HL-60 | 50μM | Apoptosis Assay | 48h | reduces cell death caused by SKI-II treatment | 25824043 |
HL-60 | 100μM | Cytotoxicity Assay | 1h | improves viability of TCNAs-treated cells | 25502932 |
HL-60 | 50µM | Apoptosis Assay | 1h | inhibits apoptosis induced by BA145 | 23948751 |
HL-60 | 100μM | Apoptosis Assay | 24h | inhibits apoptosis induced by abietane diterpenes | 23865778 |
HL-60 | 50µM | Apoptosis Assay | 4h | blocks the cleavage of caspase-3, -9, and PARP induced by 6s | 23804706 |
HL-60 | 20μM | Cytotoxicity Assay | 24h | reduces the cytotoxic effect of Ery5 | 23494480 |
HL-60 | 100μM | Apoptosis Assay | 24h | inhibits the cell apoptosis selected (+)-menthyl β-(1→6)-diglucopyranoside 5 | 22546669 |
HL-60 | 10-80μM | Apoptosis Assay | 4h | inhibits TGHQ-induced cell apoptosis | 22523229 |
HM7 | 20μM | Apoptosis Assay | 1h | blocks apicularen A acetate-induced caspase-3 activation and PARP cleavage | 23583412 |
hMSC12 | 100μM | Apoptosis Assay | 4d | inhibits osteogenic culture-induced cell death and calcification | 23657822 |
HONE-1 | 20μM | Apoptosis Assay | 24h | inhibits RAD001-induced cell death | 23426850 |
HSC-2 | 25/50μM | Apoptosis Assay | 1h | inhibits SN-38-induced cytotoxicity | 23155248 |
HSC-4 | 25/50μM | Apoptosis Assay | 1h | inhibits SN-38-induced cytotoxicity | 23155248 |
HSCs | 50μM | Apoptosis Assay | 24h | inhibits nilotinib-induced DNA damage indicated by PARP cleavage | 23499874 |
HT1080 | 50μM | Growth Inhibition Assay | 7d | inhibits the cell growth inhibition caused by combined treatment of DCA and OMP | 22740984 |
HT-29 | 50μM | Apoptosis Assay | 48h | blocks the apoptosis induced by kaempferol | 24549175 |
HUVEC-2c | 50μM | Apoptosis Assay | 6h | decreased the ox-LDL-induced autophagy | 26021729 |
HUVECs | 10μM | Apoptosis Assay | 2h | inhibits apoptosis and facilitates autophagy in DENV2-infected HUVECs | 25138703 |
IEC-6 | 10μM | Apoptosis Assay | 24h | prevents TcdA-induced caspase-3 cleavage and β-catenin degradation | 24711571 |
IM-9 B | 20μM | Apoptosis Assay | 2h | blocks anti-CD80 and anti-CD86 antibody-induced apoptosis | 24008628 |
IMR-32 | 40 μM | Apoptosis Assay | 2h | decrease in apoptotic cells compared to T-2 toxin | 25084755 |
INS-1 | 50μM | Apoptosis Assay | 6h | decreases the proportion of early apoptotic cells | 25430897 |
Ishikawa | 25μM | Apoptosis Assay | 24h | reduces cell death and apoptosis induced by Baf A1 | 22088918 |
Jurkat | 20μM | Apoptosis Assay | 24h | partially inhibit cell death of Jurkat cells induced by 10058-F4 combined with VPA | 25120723 |
Jurkat | 2μM | Cell Viability Assay | 4h | reverses growth inhibition and β-catenin decrease by HS-ASA | 23896061 |
Jurkat | 25-100μM | Cell Viability Assay | 6h | inhibits z-FA-CMK-induced cell death | 23933532 |
Jurkat | 100-200μM | Cell Viability Assay | 24h | inhibits HaA4 induces apoptosis dependent of concentration | 23732481 |
Jurkat | 12.5-50μM | Apoptosis Assay | 1h | dose dependently suppresses SPH-induced Par-4 cleavage, PARP cleavage, DNA fragmentation, and loss of viability | 23442976 |
Jurkat | 40μM | Apoptosis Assay | 1h | abolishes FasL-induced caspase activation and cell death | 22942738 |
Jurkat T | 30μM | Apoptosis Assay | 0.5h | blocks the ziram-induced apoptosis | 22159898 |
k1735 | 20 μm | Apoptosis Assay | 4h | inhibits Salmonella-induced apoptosis | 24451116 |
K562 | 50μM | Apoptosis Assay | 4h | inhibits Jac-A-induced cell apoptosis | 25241619 |
K562 | 0.1-1μM | Apoptosis Assay | 1h | inhibits cleavage of HSP90 in a dose-dependent manner | 25119188 |
K562 | 20μM | Apoptosis Assay | 48h | inhibits apoptosis induced by 4-MU | 23876826 |
K562 | 100μM | Apoptosis Assay | 1h | blocks Abnobaviscum F-induced apoptosis | 22972372 |
K562 | 25μM | Apoptosis Assay | 2h | prevents apoptosis induced by co-treatment with amurensin G and TRAIL | 22483777 |
K562 | 20 μM | Apoptosis Assay | 48h | blocks lapatinib-induced inhibition of viability and apoptosis induction | 22216158 |
KB | 50μM | Apoptosis Assay | 24h | inhibits Lico-A-induced caspase-3 and PARP activation | 24337492 |
KHOS | 40μM | Apoptosis Assay | 24h | blocks the increased cleavage of caspase-3 and PARP induced by BBMD3 | 24025361 |
KNS42 | 50μM | Apoptosis Assay | 1h | reduces cell death and completely abolished caspase 3/7 activity in response to ABT-263/2DG/metformin combination | 23691145 |
L02 | 20μM | Apoptosis Assay | 1h | prevents the cell apoptosis induced by MEHP | 24706461 |
L929 | 10μM | Apoptosis Assay | 6h | induces necroptosis with TNF | 25195660 |
L929 | 1.25–5 μM | Apoptosis Assay | 24h | augments TNFα-induced necroptosis and autophagy | 23941769 |
L929 | 2.5μM | Function Assay | 1h | increases RIP1 expression and exacerbated TNFα-induced mitochondrial dysfunction and ROS production | 23000518 |
L929 | 2.5μM | Growth Inhibition Assay | 24h | inhibits the expression of p-p38 and NF-κB to augment TNFα-induced necroptosis and autophagy | 22027097 |
L929-A | 20 μM | Cytotoxicity Assay | 24h | inhibits TNFα-induced cell death | 25398540 |
L929-N | 20 μM | Cytotoxicity Assay | 24h | enhances death via autocrine TNFα production | 25398540 |
LCC9 | 100μM | Cell Viability Assay | 5d | blocks cell death induced by combination L17 and chloroquine | 24785256 |
LLC-PK1 | 20μM | Apoptosis Assay | 1h | prevents cisplatin-induced degradation of Atg5, beclin-1, and Atg12 proteins | 22896037 |
LNCaP | 40μM | Apoptosis Assay | 2h | inhibits butein induced cell apoptosis | 22114764 |
LNCaP | 50 μM | Apoptosis Assay | 24h | abrogates curcumin-induced cell death | 22101335 |
LOVO | 10 µM | Apoptosis Assay | 1h | restrains cell apoptosis induced by gefitinib plus decitabine | 24874286 |
M-14 | 25μM | Apoptosis Assay | 0.5h | inhibits both the crude extract- and compound-induced apoptosis | 21954959 |
macrophage | 0-200μM | Cell Viability Assay | 24h | induces TNF- and Rip3-dependent necroptosis in macrophage | 24799565 |
MB231 | 100μM | Apoptosis Assay | 1h | abrogates the induction of cell death by WEE1 inhibition, TRAIL treatment, and the combination | 22112940 |
MB49 | 20μM | Apoptosis Assay | 1h | reverses CM-induced cell death | 24282433 |
MCC-2 | 20 μM | Apoptosis Assay | 6h | blocks induced by staurosporine apoptosis cell death | 24262658 |
MCF7 | 50 μM | Apoptosis Assay | 1h | inhibits PA activated caspase-3, -9, and poly(ADP-ribose) polymerase | 22223345 |
MCF-7 | 10μM | Apoptosis Assay | 2h | inhibits the cell death induced by 3B | 25722114 |
MCF-7 | 20μM | Apoptosis Assay | 2h | decreases KDR-siRNA-induced apoptosis | 25182240 |
MCF-7 | 20μM | Apoptosis Assay | 72h | inhibits equol- and 4-OHT-mediated apoptosis | 23675643 |
MCF-7, MDA-MB-468, Caco-2 | 50μM | Growth Inhibition Assay | 48h | inhibits the cell growth inhibition induced by saponin | 22800968 |
MDA-MB231 | 50 μM | Apoptosis Assay | 24h | abrogates curcumin-induced cell death | 22101335 |
MDA-MB-231 | 10μM | Cytotoxicity Assay | 1h | augments cell death after CHUA treatment | 25521501 |
MDA-MB-231 | 25μM | Apoptosis Assay | 24h | abrogates cytotoxicity and cleavage of caspase-3 and PARP induced by Rg3 | 25337544 |
MDA-MB-231 | 100μM | Apoptosis Assay | 1h | inhibits sensitization to TRAIL upon MTDH down-regulation | 23408429 |
MDA-MB-231 | 20μM | Apoptosis Assay | 4d | reduces the cell apoptosis induced by metformin treatment was significantly | 22593441 |
MDA-MB-231 | 2.5-7.5μM | Apoptosis Assay | 2h | inhibits the cell death of MDA-MB-231 cells induced by SDT in a concentration dependent manner | 22115526 |
MDA-MB-468 | 50 μM | Apoptosis Assay | 2h | blocks apoptotic DNA fragmentation induced by combination of SM-164 and radiation | 21901386 |
MEL | 20μM | Apoptosis Assay | 24h | impaires P2X7-induced MEL cell apoptosis | 23014887 |
MEL | 20μM | Apoptosis Assay | 1h | impaires P2X7-induced MEL cell apoptosis | 23014887 |
mESCs | 2.5μM | Apoptosis Assay | 2h | inhibits the NaF-mediated caspase activation | 22285274 |
MG-63 | 40μM | Apoptosis Assay | 24h | blocks the increased cleavage of caspase-3 and PARP induced by BBMD3 | 24025361 |
MIA-PaCa-2 | - | Apoptosis Assay | 24h | blocks cleavage of caspase-3 induced by both A-443654 and paclitaxel | 24510992 |
MKN28 | 10μM | Apoptosis Assay | 30min | inhibits TNF-α plus CHX-induced apoptosis | 25513960 |
MM | 50μM | Apoptosis Assay | 20min | partly inhibits SHK-induced cell death | 25530098 |
MM.1S | 100μM | Apoptosis Assay | 1h | efficiently prevents sorafenib-induced cell death combine with necrostatin-1 | 25037851 |
Molt-3 | 50μM | Apoptosis Assay | 2h | reduces melatonin-induced apoptosis | 23725013 |
Molt4-hyg | 10μM | Apoptosis Assay | 0.5h | blocks farnesol-induced caspase-3-like activity | 26275811 |
Nalm-6 | 20μM | Apoptosis Assay | 4h | inhibits caspase-8 and caspase-3 activation and PARP-1 cleavage | 24039967 |
NB2a/d1 | 100μM | Apoptosis Assay | 72h | attenuates staurosporine-induced caspase activity, PARP, and tau cleavage | 22988541 |
NBL-W-S | 50μM | Apoptosis Assay | 1h | fully rescues cell viability after GANT-61 treatment | 25323222 |
Neocortical Neuron | 100μM | Neurotoxicity Assay | 1h | antagonizes Hoiamide A-Induced Neurotoxicity | 25675001 |
Neutrophil | 20μM | Apoptosis Assay | 0.5h | attenuates the pro-apoptotic effect of MaR1 | 26196844 |
NLRP3-Tet-on-MC/9 | 10-40μM | Apoptosis Assay | 12h | attenuates the cell death caused by CAPS-associated NLRP3 mutants in the Tet-on system | 23703389 |
OS | 20/40μM | Apoptosis Assay | 72h | inhibits OS cell viability reduction by C6 ceramide | 25152399 |
OS | 20μM | Apoptosis Assay | 4h | inhibits the cell death caused by PDT | 24204937 |
P815 | 100 µM | Apoptosis Assay | 12h | inhibits virus-induced apoptosis | 24923273 |
PC3 | 10μM | Apoptosis Assay | 4h | counters flavocoxid-induced caspase-related apoptosis | 22471974 |
PDL fibroblasts | 80μM | Kinase Assay | 1h | inhibits Caspase-3 activity | 24314135 |
PLC/PRF/5c | 50μM | Apoptosis Assay | 1h | prevents apoptosis triggered by CIN | 23438824 |
PMNs | 40μM | Apoptosis Assay | 6h | reversed the amount of cleaved caspase-3 to near vehicle levels | 22692577 |
podocytes | 200μM | Apoptosis Assay | 6h | inhibits apoptosis induced by 3,4-DGE | 24337777 |
Primary hepatocytes | 50μM | Apoptosis Assay | 18h | inhibits apoptosis of hepatocytes induced by Act D and TNF-α | 25407538 |
Primary human placental cytotrophoblasts | 30μM | Apoptosis Assay | 24h | reverses the inhibition of 11β-HSD2 by triclosan | 25642592 |
primary MEFs | - | Function Assay | 12h | increases etoposide-induced mitochondrial membrane depolarization | 22613767 |
Primary OPC | 1μM | Apoptosis Assay | 6h/24h | reduces the percentage of cells in early- and late-apoptosis/necrosis | 22707385 |
Primary rat cerebral cortical neurons | 100μM | Apoptosis Assay | 1h | prevents Cd-induced apoptosis and cell death | 23741317 |
QGY7701 | 25μM | Apoptosis Assay | 1.5h | inhibits accumulation of sub-G1 phase induced by DOX + quercetin | 23240061 |
RAW 264.7 | 20μM | Apoptosis Assay | 18h | increases LC3-II/β-actin ratio compared to ECTV-MOS treatment only | 24116707 |
RAW 264.7 | 50/100μM | Apoptosis Assay | 1h | concentration-dependent inhibits DON-induced rRNA cleavage | 22491426 |
RAW264.7 | 10 μM | Apoptosis Assay | 24h | decreases the apoptosis induced by GA | 23820203 |
RCC | 100μM | Cell Viability Assay | 24h | recoveres the viability of cells exposed to 15d-PGJ2 | 22991494 |
RKO | 10 μM | Cell Viability Assay | 24h | inhibits the decrease of cell viability caused by DAB | 23758064 |
RKO-HIPK2i | 40μM | Apoptosis Assay | 6h | inhibits apoptosis induced by chemotherapy plus ZnCl2 | 24228232 |
RPE | 100μM | Apoptosis Assay | 48h | partially inhibits the calpain-1 and -2 activation as well as the caspase activation | 24202052 |
RPMI 8226 | 100μM | Apoptosis Assay | 1h | almost completely blocks cell death caused by necrostatin-1 | 25037851 |
SCCVII | 25μM | Apoptosis Assay | 1h | inhibits the cell killing after dasatinib | 24126464 |
SGC-7901 | 20 μM | Apoptosis Assay | 1h | inhibits the cell death induced by oxaliplatin | 25767076 |
SGC-7901 | 10μM | Apoptosis Assay | 24h | promotes the CGII-inhibited cell growth in SGC-7901 cells | 24454488 |
SGC-7901 | 10μM | Apoptosis Assay | 24h | inhibits β,β-dimethylacrylshikonin-induced apoptosis | 22848597 |
SGC-7901 | 20 μM | Apoptosis Assay | 2h | attenuates H2O2 or TNF α-induced cell apoptosis as well as caspase-3 activity | 22471589 |
SGN | 20mM | Apoptosis Assay | 48h | has no influence on AIF, calpain expression or cell apoptosis | 25874633 |
shC9 | 10μM | Apoptosis Assay | 16h | blunts SHH expression in shC9 cells exposed to either PA or LPC | 22641094 |
SH-SY5Y | 10μM | Apoptosis Assay | 24h | attenuates caspase activation and cell death induced by HNE-2DG | 24145463 |
SK-BR-3 | 50 μM | Apoptosis Assay | 2h | blocks apoptotic DNA fragmentation induced by combination of SM-164 and radiation | 21901386 |
SK-HEP1 | 100μM | Apoptosis Assay | 1h | inhibits CrT1 activated caspase-3, -7, -8, -9, and poly(ADP-ribose) polymerase | 23302650 |
SMMC-7721 | 50μM | Apoptosis Assay | 48h | attenuates oTR-induced apoptosis | 22465833 |
SNU449 | 20μM | Apoptosis Assay | 48h | decreases miR-451-induced apoptotic | 24841638 |
SP2/0 | 100μM | Apoptosis Assay | 1h | blocks the apoptosis of SP2/0 cells | 26074732 |
SW1116 | 10 µM | Apoptosis Assay | 1h | restrains cell apoptosis induced by gefitinib plus decitabine | 24874286 |
T cell | 0-100μM | Cell proliferation assay | 72h | IC50=70 μM, inhibits anti-CD3-induced T cell proliferation in PBMCs | 24768707 |
T cell | 25-100μM | Growth Inhibition Assay | 24h | dose-dependently inhibited T cell proliferation mediated through the co-stimulation with anti-CD3 and anti-CD28 | 22982538 |
T47D | 100μM | Apoptosis Assay | 1h | blocks the generation of E-cad/CTF2 by STS | 22401168 |
T98G | 1-100μM | Cell Viability Assay | 24h | improves cell viability cotreatment with TS | 23769275 |
THP-1 | 10μM | Apoptosis Assay | 1h | reduces apoptosis induced by ALA-SDT | 24923653 |
THP-1 | 10-50μM | Apoptosis Assay | 2h | inhibits apoptosis induced by triptolide | 23900299 |
U1 | 0-100μM | Apoptosis Assay | 2h | reduces drug-induced apoptosis and subsequent HIV-1 replication in a dose-dependent manner | 25980942 |
U1 | 100μM | Kinase Assay | 2h | inhibits caspase-3 | 25980942 |
U251 | 20μM | Apoptosis Assay | 24h | inhibits casticin induced G2/M phase arrest and apoptosis | 23816816 |
U266 | 100μM | Apoptosis Assay | 1h | partially blocks cell death caused by necrostatin-1 | 25037851 |
U373 | 40μM | Apoptosis Assay | 6h | inhibits apoptosis induced by chemotherapy plus ZnCl2 | 24228232 |
U87 | 50μM | Growth Inhibition Assay | 1h | recovers cell growth from TMZ treatment | 25681668 |
U87 | 25μM | Apoptosis Assay | 2h | decreases isoliquiritigenin (ISL)-induced apoptotic cell death, but not necrotic cell death | 23229626 |
U87 | 20μM | Apoptosis Assay | 24h | reduces the apoptosis rate induced by PLAB | 22778780 |
U937 | 50μM | Apoptosis Assay | 48h | reduces cell death caused by SKI-II treatment | 25824043 |
U937 | 10 μM | necroptosis Assay | 30 min | induces necroptosis combine with TNF | 24773756 |
U937 | 50 μM | Apoptosis Assay | 1h | inhibits HF-induced apoptosis | 21998731 |
U-937 | 10μM | Apoptosis Assay | 30min | prevents TNF-induced necroptosis | 23410748 |
UD29a | 50μM | Apoptosis Assay | 24h | inhibits the cell death caused by NUT3 | 24190574 |
UM-SCC-10A | 50µM | Apoptosis Assay | 2h | reduces apoptosis induced by high-dose isoalantolactone | 24098753 |
YD-8 | 100μM | Apoptosis Assay | 1h | inhibits PLEO-induced apoptosis | 22086183 |
YD-8 | 100μM | Apoptosis Assay | 1h | blocks the GS-HCl-induced apoptosis | 22020078 |
靶点 | Description | IC50 |
---|
联系我们
官方电话:400-920-2911
二维码
微信公众号 CSN官网